Innate Pharma SA (IPHA)
2.710
+0.14
(+5.28%)
USD |
NASDAQ |
May 17, 16:00
2.73
+0.02
(+0.74%)
After-Hours: 20:00
Innate Pharma Enterprise Value: 160.05M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 160.05M |
| May 16, 2024 | 149.06M |
| May 15, 2024 | 143.59M |
| May 14, 2024 | 154.40M |
| May 13, 2024 | 151.96M |
| May 10, 2024 | 145.50M |
| May 09, 2024 | 143.64M |
| May 08, 2024 | 153.59M |
| May 07, 2024 | 148.74M |
| May 06, 2024 | 142.27M |
| May 03, 2024 | 146.75M |
| May 02, 2024 | 137.42M |
| May 01, 2024 | 146.31M |
| April 30, 2024 | 127.72M |
| April 29, 2024 | 140.65M |
| April 26, 2024 | 139.85M |
| April 25, 2024 | 134.99M |
| April 24, 2024 | 139.85M |
| April 23, 2024 | 132.57M |
| April 22, 2024 | 137.02M |
| April 19, 2024 | 138.23M |
| April 18, 2024 | 130.95M |
| April 17, 2024 | 135.80M |
| April 16, 2024 | 150.35M |
| April 15, 2024 | 136.61M |
| Date | Value |
|---|---|
| April 12, 2024 | 141.46M |
| April 11, 2024 | 141.46M |
| April 10, 2024 | 144.70M |
| April 09, 2024 | 151.16M |
| April 08, 2024 | 151.16M |
| April 05, 2024 | 145.71M |
| April 04, 2024 | 143.08M |
| April 03, 2024 | 148.74M |
| April 02, 2024 | 144.70M |
| April 01, 2024 | 157.63M |
| March 28, 2024 | 173.80M |
| March 27, 2024 | 133.38M |
| March 26, 2024 | 138.23M |
| March 25, 2024 | 134.99M |
| March 22, 2024 | 132.77M |
| March 21, 2024 | 135.81M |
| March 20, 2024 | 143.08M |
| March 19, 2024 | 137.42M |
| March 18, 2024 | 134.19M |
| March 15, 2024 | 145.10M |
| March 14, 2024 | 144.70M |
| March 13, 2024 | 143.08M |
| March 12, 2024 | 151.16M |
| March 11, 2024 | 138.63M |
| March 08, 2024 | 159.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
68.86M
Minimum
Dec 16 2022
519.78M
Maximum
Sep 17 2021
203.02M
Average
177.02M
Median
Enterprise Value Benchmarks
| Sanofi SA | 130.04B |
| DBV Technologies SA | 10.92M |
| Cellectis SA | 44.93M |
| PHAXIAM Therapeutics SA (DELISTED) | -8.542M |
| Genfit SA | 172.52M |
Enterprise Value Related Metrics
| Earnings Yield | -3.57% |
| Normalized Earnings Yield | -3.567 |